- Home
- ENSG vs VRNA Comparison
ENSG vs VRNA Comparison
Compare ENSG & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSG
- VRNA
- Stock Information
- Founded
- ENSG 1999
- VRNA 2005
- Country
- ENSG United States
- VRNA United Kingdom
- Employees
- ENSG N/A
- VRNA N/A
- Industry
- ENSG Hospital/Nursing Management
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- ENSG Health Care
- VRNA Health Care
- Exchange
- ENSG Nasdaq
- VRNA Nasdaq
- Market Cap
- ENSG 7.3B
- VRNA 7.8B
- IPO Year
- ENSG 2007
- VRNA 2017
- Fundamental
- Price
- ENSG $153.54
- VRNA $92.20
- Analyst Decision
- ENSG Buy
- VRNA Strong Buy
- Analyst Count
- ENSG 7
- VRNA 7
- Target Price
- ENSG $164.71
- VRNA $97.57
- AVG Volume (30 Days)
- ENSG 342.6K
- VRNA 1.4M
- Earning Date
- ENSG 07-24-2025
- VRNA 08-07-2025
- Dividend Yield
- ENSG 0.16%
- VRNA N/A
- EPS Growth
- ENSG 39.72
- VRNA N/A
- EPS
- ENSG 5.30
- VRNA N/A
- Revenue
- ENSG $4,423,354,000.00
- VRNA $118,535,000.00
- Revenue This Year
- ENSG $17.71
- VRNA $891.79
- Revenue Next Year
- ENSG $9.69
- VRNA $78.94
- P/E Ratio
- ENSG $29.02
- VRNA N/A
- Revenue Growth
- ENSG 14.81
- VRNA N/A
- 52 Week Low
- ENSG $118.73
- VRNA $14.14
- 52 Week High
- ENSG $158.45
- VRNA $94.45
- Technical
- Relative Strength Index (RSI)
- ENSG 64.01
- VRNA 78.05
- Support Level
- ENSG $147.59
- VRNA $82.18
- Resistance Level
- ENSG $157.68
- VRNA $93.74
- Average True Range (ATR)
- ENSG 3.21
- VRNA 3.21
- MACD
- ENSG -0.12
- VRNA 0.89
- Stochastic Oscillator
- ENSG 66.61
- VRNA 92.52
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.